Curis (NASDAQ: CRIS) reported Q1 EPS of ($0.28), versus ($0.30) reported last year. Revenue for the quarter came in at $2.52 million versus the consensus estimate of $2.4 million.

"The first quarter of 2020 was productive for Curis, as we advanced our ongoing study for CA-4948 and accomplished several key licensing and financial objectives to support future progress across our pipeline and business,\" said James Dentzer, President and Chief Executive Officer of Curis. \"In response to the COVID-19 pandemic, we have implemented both clinical and operational measures to help protect patients, staff, study investigators and our community, and I am incredibly proud of the resiliency and dedication our team continues to demonstrate during this difficult period. We look forward to updating efficacy data from our CA-4948 study in patients with non-Hodgkin\'s lymphoma (NHL) and remain on track to pursue clinical testing of CA-4948 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), two areas of critical unmet need."

For earnings history and earnings-related data on Curis (CRIS) click here.